AAP
IMNM icon

Arax Advisory Partners’s Immunome IMNM Stock Holding History

Arax Advisory Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19
Closed -$408 – 4060
2025
Q4 		$408 Sell
19
-101
-84% -$1.77K ﹤0.01% 3636
2025
Q3 		$1.41K Buy
+120
New +$1.19K ﹤0.01% 3182
2025
Q2 		– Sell
-69
Closed -$465 – 3126
2025
Q1 		$465 Buy
+69
New +$662 ﹤0.01% 2543

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Arax Advisory Partners's IMNM Position: Q1 2026 in Review

Arax Advisory Partners sold out of Immunome (IMNM) in Q1 2026, closing a stake of 19 shares — an estimated $408 sold.

Arax Advisory Partners first reported a position in IMNM in Q1 2025 and held it in 3 quarters. The position peaked at $1.41K in Q3 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Arax Advisory Partners reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 19 Immunome shares in Q1 2026, an estimated $408.
  • Arax Advisory Partners first reported a position in Immunome in Q1 2025 and held it in 3 quarters.
  • Arax Advisory Partners's Immunome position peaked at $1.41K in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.